Skip to main content
SpringerLink
Log in

Biological Approach in the Treatment of Crohn’s Disease

  • Chapter
Inflammatory Bowel Disease and Familial Adenomatous Polyposis

  • 796 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12(Suppl 1):S3–S9

    Article  PubMed  Google Scholar 

  2. Gustot T, Lemmers A, Louis E et al (2005) Profile of soluble cytokine receptors in Crohn’s disease. Gut 54:488–495

    Article  PubMed  CAS  Google Scholar 

  3. Lindsay JO, Hodgson HJ (2001) Review article: the immunoregulatory cytokine interleukin-10 — a therapy for Crohn’s disease? Aliment Pharmacol Ther 15:1709–1716

    Article  PubMed  CAS  Google Scholar 

  4. Sandborn WJ, Targan SR (2002) Biologic therapy of inflammatory bowel disease. Gastroenterology 122:1592–1608

    Article  PubMed  CAS  Google Scholar 

  5. Vermeire S, Rutgeerts P (2004) Novel biological strategies in inflammatory bowel diseases. Inflamm Bowel Dis 10:s44–s51

    Article  PubMed  Google Scholar 

  6. Papadakis KA, Targan S (2000) Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119:1148–1157

    Article  PubMed  CAS  Google Scholar 

  7. van den Brande J, Hommes DW, Peppelenbosch MP (2005) Infliximab induced T lymphocyte apoptosis in Crohn’s disease. J Rheumatol 74(Suppl):26–30

    Google Scholar 

  8. Sandborn WJ, Hanauer SB (1999) Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5:119–133

    Article  PubMed  CAS  Google Scholar 

  9. Ringheanu M, Daum F, Markowitz J et al (2004) Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn’s disease. Inflamm Bowel Dis 10:801–810

    Article  PubMed  Google Scholar 

  10. D’Haens G, Van Deventer S, Van Hogezand R et al (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 116:1029–1034

    Article  PubMed  CAS  Google Scholar 

  11. Geboes K, Rutgeerts P, Opdenakker G et al (2005) Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment of Crohn’s diseas. Curr Med Res Opin 21:1741–1754

    Article  PubMed  CAS  Google Scholar 

  12. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549

    Article  PubMed  CAS  Google Scholar 

  13. Sandborn WJ, Hanauer SB (2002) Infliximab in the treatment of Crohn’s disease: a user’s guide for clinicians. Am J Gastroenterol 97:2962–2972

    Article  PubMed  CAS  Google Scholar 

  14. Rutgeerts PJ (2001) Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther 15:1515–1525

    Article  PubMed  CAS  Google Scholar 

  15. Laine L, Hanauer SB (2003) Considerations in the management of steroid-dependent Crohn’s disease. Gastroenterology 125:906–910

    Article  PubMed  Google Scholar 

  16. Hanauer SB (2003) Crohn’s disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 17:131–137

    Article  PubMed  Google Scholar 

  17. Targan SR, Hanauer SB, van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA 2 Study Group. N Engl J Med 337:1029–1035

    Article  PubMed  CAS  Google Scholar 

  18. van Dullemen HM, van Deventer SJ, Hommes DW et al (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129–135

    Article  PubMed  Google Scholar 

  19. Baert FJ, D’Haens GR, Peeters M et al (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28

    Article  PubMed  CAS  Google Scholar 

  20. Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405

    Article  PubMed  CAS  Google Scholar 

  21. Rutgeerts P, D’Haens G, Targan S et al (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117:761–769

    Article  PubMed  CAS  Google Scholar 

  22. Farrell RJ, Shah SA, Lodhavia PJ et al (2000) Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 95:3490–3497

    Article  PubMed  CAS  Google Scholar 

  23. Cohen RD (2001) Efficacy and safety of repeated infliximab infusions for Crohn’s disease: 1-year clinical experience. Inflamm Bowel Dis 7(Suppl 1):S17–S22

    PubMed  Google Scholar 

  24. Arnott ID, McDonald D, Williams A, Ghosh S (2001) Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience. Aliment Pharmacol Ther 15:1639–1646

    Article  PubMed  CAS  Google Scholar 

  25. Hommes DW, van de Heisteeg BH, van der Spek M, et al (2002) Infliximab treatment for Crohn’s disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 8:81–86

    Article  PubMed  Google Scholar 

  26. Ardizzone S, Colombo E, Maconi G et al (2002) Infliximab in treatment of Crohn’s disease: the Milan experience. Dig Liver Dis 34:411–418

    Article  PubMed  CAS  Google Scholar 

  27. Arslan S, Kav T, Besisik F et al (2003) Clinical outcome of Crohn’s disease treated with infliximab. Hepatogastroenterology 50:952–956

    PubMed  CAS  Google Scholar 

  28. Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885

    Article  PubMed  CAS  Google Scholar 

  29. Wenzl HH, Reinisch W, Jahnel J et al (2004) Austrian infliximab experience in Crohn’s disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol 16:767–773

    Article  PubMed  CAS  Google Scholar 

  30. Orlando A, Colombo E, Kohn A et al (2005) Infliximab in the treatment of Crohn’s disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 37:577–583

    Article  PubMed  CAS  Google Scholar 

  31. Centocor, Inc. (2002) Remicade (infliximab) for i.v. injection. Volume Package insert. Melvern, PA

    Google Scholar 

  32. Rutgeerts P, Mayer L, Schreiber S (2001) Infliximab (Remicade) maintenance treatment strategy is superior to episodic treatment in patients with Crohn’s disease. Am J Gastroenterol 96:S302–S303

    Article  Google Scholar 

  33. Menachem Y, Avidan B, Lavy A et al (2005) Increasing the infliximab dose is beneficial in Crohn’s disease patients who responded to a lower dose and relapsed. Digestion 72:124–128

    Article  PubMed  CAS  Google Scholar 

  34. Allan A, Keighley RB (1988) Management of perianal disease. World J Surg 12:198–202

    Article  PubMed  CAS  Google Scholar 

  35. Regueiro M, Mardini H (2003) Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 9:98–103

    Article  PubMed  Google Scholar 

  36. Present DH (2003) Crohn’s fistula: current concepts in management. Gastroenterology 124:1629–1635

    Article  PubMed  Google Scholar 

  37. Felley C, Mottet C, Juillerat P et al (2005) Fistulizing Crohn’s disease. Digestion 71:26–28

    Article  PubMed  Google Scholar 

  38. Schroder O, Blumenstein I, Schulte-Bockholt A, Stein J (2004) Combining infliximab and methotrexate in fistulizing Crohn’s disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther 19:295–301

    Article  PubMed  CAS  Google Scholar 

  39. Talbot C, Sagar PM, Johnston MJ et al (2005) Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Colorectal Dis 7:164–168

    Article  PubMed  CAS  Google Scholar 

  40. Poggioli G, Laureati S, Pierangeli F et al (2005) Local injection of infliximab for the tratment of perianal Crohn’s disease. Dis Colon Rectum 48:768–774

    Article  PubMed  CAS  Google Scholar 

  41. Parsi MA, Lashner BA, Achkar JP et al (2004) Type of fistula determines response to infliximab in patients with fistulous Crohn’s disease. Am J Gastroenterol 99:445–449

    Article  PubMed  CAS  Google Scholar 

  42. Wheeler C, Marion JF, Present DH (1998) Medical therapy, not surgery, is the appropriate first line treatement of Crohn’s enterovesical fistula. Gastroenterology 114A:1113

    Article  Google Scholar 

  43. Sonoda T, Haull T, Piedmonte MR, Fazzi M (2002) Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap. Dis Colon Rectum 45:1622–1628

    Article  PubMed  Google Scholar 

  44. Sorrentino D, Avellini C, Beltrami CA et al (2005) Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn’s disease. Int J Colorectal Dis [Epub ahead of print]

    Google Scholar 

  45. Parsi MA, Achkar JP, Richardson S et al (2002) Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology 123:707–713

    Article  PubMed  CAS  Google Scholar 

  46. Arnott ID, McNeill G, Satsangi J (2003) An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther 17:1451–1457

    Article  PubMed  CAS  Google Scholar 

  47. Holtmann MH, Neurath MF (2005) Anti-TNF strategies in stenosing and fistulizing Crohn’s disease. Int J Colorectal Dis 20:1–8

    Article  PubMed  Google Scholar 

  48. Biancone L, Tosti C, Fina D et al (2003) Review article: maintenance treatment of Crohn’s disease. Aliment Pharmacol Ther 17(Suppl 2):31–37

    Article  PubMed  CAS  Google Scholar 

  49. Boirivant M, Leoni M, Tariciotti D et al (1988) The clinical significance of serum C reactive protein levels in Crohn’s disease. Results of a prospective longitudinal study. J Clin Gastroenterol 10:401–405

    Article  PubMed  CAS  Google Scholar 

  50. Ollendorf DA, Massarotti E, Birbara C, Burgess SM (2005) Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 11:383–393

    PubMed  Google Scholar 

  51. Lichtenstein GR, Yan S, Bala M et al (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 128:862–869

    Article  PubMed  CAS  Google Scholar 

  52. Bodger K (2005) Economic implications of biological therapies for Crohn’s disease: review of infliximab. Pharmacoeconomics 23:875–888

    Article  PubMed  Google Scholar 

  53. Cadahia V, Garcia-Carbonero A, Vivas S et al (2004) Infliximab improves quality of life in the short-term in patients with fistulizing Crohn’s disease in clinical practice. Rev Esp Enferm Dig 96:369–374; 374–378

    Article  PubMed  CAS  Google Scholar 

  54. Clark W, Raftery J, Song F et al (2003) Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol Assess 7:1–67

    PubMed  CAS  Google Scholar 

  55. Wicks AC, Thomas C, Curran R, Mayberry JF (2002) Infliximab and Crohn’s QOL. Aliment Pharmacol Ther 16:1831–1832

    Article  PubMed  CAS  Google Scholar 

  56. Hommes DW, van Deventer SJ (2003) Infliximab therapy in Crohn’s disease: safety issues. Neth J Med 61:100–104

    PubMed  CAS  Google Scholar 

  57. Colombel JF, Loftus EV Jr, Tremaine WJ et al (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126:19–31

    Article  PubMed  CAS  Google Scholar 

  58. Hanauer SB (1999) Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 13(Suppl 4):16–22; discussion 38

    Article  PubMed  CAS  Google Scholar 

  59. Cheifetz A, Smedley M, Martin S et al (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98:1315–1324

    Article  PubMed  CAS  Google Scholar 

  60. Farrell RJ, Alsahli M, Jeen YT et al (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 124:917–924

    Article  PubMed  CAS  Google Scholar 

  61. Sandborn WJ (2003) Preventing antibodies to infliximab in patients with Crohn’s disease: optimize not immunize. Gastroenterology 124:1140–1145

    PubMed  CAS  Google Scholar 

  62. Baert F, Noman M, Vermeire S et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348:601–608

    Article  PubMed  CAS  Google Scholar 

  63. Hanauer SB, Wagner CL, Bala M et al (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2:542–553

    Article  PubMed  CAS  Google Scholar 

  64. Rutgeerts P, Van Assche G, Vermeire S (2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126:1593–1610

    Article  PubMed  CAS  Google Scholar 

  65. Han PD, Cohen RD (2004) Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs 64:1767–1777

    Article  PubMed  CAS  Google Scholar 

  66. Crandall WV, Mackner LM (2003) Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 17:75–84

    Article  PubMed  CAS  Google Scholar 

  67. Gardam MA, Keystone EC, Menzies R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148–155

    Article  PubMed  CAS  Google Scholar 

  68. Beenhouwer D, Wallis R, Broder M, Furst DE (2004) Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections. J Rheumatol 31:1888–1892

    PubMed  Google Scholar 

  69. Wallis RS, Broder M, Wong J et al (2005) Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41(Suppl 3):S194–S198

    Article  PubMed  CAS  Google Scholar 

  70. Wallis RS, Broder MS, Wong JY et al (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265

    Article  PubMed  CAS  Google Scholar 

  71. Velayos FS, Sandborn WJ (2004) Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 10:657–660

    Article  PubMed  Google Scholar 

  72. Keane J, Gershon S, Wise RP, Mirabile-Levens E et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104

    Article  PubMed  CAS  Google Scholar 

  73. Warris A, Bjorneklett A, Gaustad P (2001) Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 344:1099–1100

    Article  PubMed  CAS  Google Scholar 

  74. Hamilton CD (2004) Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 16:393–398

    Article  PubMed  Google Scholar 

  75. Listing J, Strangfeld A, Kary S et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403–3412

    Article  PubMed  CAS  Google Scholar 

  76. Ormerod LP (2004) Tuberculosis and anti-TNF-alpha treatment. Thorax 59:921

    Article  PubMed  CAS  Google Scholar 

  77. De Rosa FG, Bonora S, Di Perri G (2002) Tuberculosis and treatment with infliximab. N Engl J Med 346:623–626

    Article  PubMed  Google Scholar 

  78. Zhang Z, Correa H, Begue RE (2002) Tuberculosis and treatment with infliximab. N Engl J Med 346:623–626

    Article  PubMed  Google Scholar 

  79. Morelli J, Wilson FA (2000) Does administration of infliximab increase susceptibility to listeriosis? Am J Gastroenterol 95:841–842

    Article  PubMed  CAS  Google Scholar 

  80. Tai TL, O’Rourke KP, McWeeney M et al (2002) Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 41:951–952

    Article  PubMed  CAS  Google Scholar 

  81. Seddik M, Meliez H, Seguy D et al (2004) Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn’s disease. Inflamm Bowel Dis 10:436–437

    Article  PubMed  Google Scholar 

  82. Kaur N, Mahl TC (2004) Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn’s disease. Dig Dis Sci 49:1458–1460

    Article  PubMed  Google Scholar 

  83. Seddik M, Melliez H, Seguy D et al (2005) Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn’s disease. Inflamm Bowel Dis 11:618–620

    Article  PubMed  Google Scholar 

  84. Wood KL, Hage CA, Knox KS et al (2003) Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 167:1279–1282

    Article  PubMed  Google Scholar 

  85. Lee JH, Slifman NR, Gershon SK et al (2002) Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46:2565–2570

    Article  PubMed  CAS  Google Scholar 

  86. Nakelchik M, Mangino JE (2002) Reactivation of histoplasmosis after treatment with infliximab. Am J Med 112:78

    Article  PubMed  Google Scholar 

  87. Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P (2004) Listeria meningitis associated with infliximab. Ann Pharmacother 38:58–61

    Article  PubMed  Google Scholar 

  88. Aparicio AG, Munoz-Fernandez S, Bonilla G et al (2003) Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Gluck et al. Arthritis Rheum 48:1764–1765; author reply 1765–1766

    Article  PubMed  Google Scholar 

  89. Slifman NR, Gershon SK, Lee JH et al (2003) Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 48:319–324

    Article  PubMed  CAS  Google Scholar 

  90. Kamath BM, Mamula P, Baldassano RN, Markowitz JE (2002) Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 34:410–412

    Article  PubMed  Google Scholar 

  91. Gluck T, Linde HJ, Scholmerich J et al (2002) Antitumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 46:2255–2257; author reply 2257

    Article  PubMed  CAS  Google Scholar 

  92. Alderson JW, Van Dinter TG Jr et al (2005) Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn’s disease and chronic hepatitis C: a case study and review of the literature. MedGenMed 7:7

    PubMed  Google Scholar 

  93. van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM et al (2003) Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 29:2327–2329

    Article  PubMed  Google Scholar 

  94. De Rosa FG, Shaz D, Campagna AC et al (2003) Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 24:477–482

    Article  PubMed  Google Scholar 

  95. Marinos G, Naoumov NV, Rossol S et al (1995) Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 108:1453–1463

    Article  PubMed  CAS  Google Scholar 

  96. Tilg H (1997) New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112:1017–1021

    Article  PubMed  CAS  Google Scholar 

  97. del Valle Garcia-Sanchez M, Gomez-Camacho F et al (2004) Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 10:701–702

    Article  PubMed  Google Scholar 

  98. Campbell S, Ghosh S (2001) Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 13:191–192

    Article  PubMed  CAS  Google Scholar 

  99. Peterson JR, Hsu FC, Simkin PA, Wener MH (2003) Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62:1078–1082

    Article  PubMed  CAS  Google Scholar 

  100. Biancone L, Pavia M, Del Vecchio Blanco G et al (2001) Hepatitis B and C virus infection in Crohn’s disease. Inflamm Bowel Dis 7:287–294

    Article  PubMed  CAS  Google Scholar 

  101. Holtmann MH, Galle PR, Neurath MF (2003) Treatment of patients with Crohn’s disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 98:504–505

    Article  PubMed  Google Scholar 

  102. Biancone L, Del Vecchio Blanco G et al (2002) Immunomodulatory drugs in Crohn’s disease patients with hepatitis B or C virus infection. Gastroenterology 122:593–594

    PubMed  Google Scholar 

  103. Wendling D, Auge B, Bettinger D et al (2005) Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64:788–789

    Article  PubMed  CAS  Google Scholar 

  104. Ueno Y, Tanaka S, Shimamoto M et al (2005) Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sci 50:163–166

    Article  PubMed  Google Scholar 

  105. Esteve M, Saro C, Gonzalez-Huix F et al (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 53:1363–1365

    Article  PubMed  CAS  Google Scholar 

  106. Ostuni P, Botsios C, Punzi L et al (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62:686–687

    Article  PubMed  CAS  Google Scholar 

  107. Michel M, Duvoux C, Hezode C, Cherqui D (2003) Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol 30:1624–1625

    PubMed  Google Scholar 

  108. Sandborn WJ, Loftus EV (2004) Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 53:780–782

    Article  PubMed  CAS  Google Scholar 

  109. Biancone L, Orlando A, Kohn A et al (2006) Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study. Gut 55:228–233

    Article  PubMed  CAS  Google Scholar 

  110. Kandiel A, Fraser AG, Korelitz BI et al (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54:1121–1125

    Article  PubMed  CAS  Google Scholar 

  111. Tan CW, Wilson GE, Howat JM, Shreeve DR (2001) Rectal lymphoma in ulcerative colitis treated with azathioprine. Eur J Gastroenterol Hepatol 13:989–992

    Article  PubMed  CAS  Google Scholar 

  112. Lewis JD, Schwartz JS, Lichtenstein GR (2000) Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology 118:1018–1024

    Article  PubMed  CAS  Google Scholar 

  113. Phillips T, Salisbury J, Leigh I, Baker H (1987) Non-Hodgkin’s lymphoma associated with long-term azathioprine therapy. Clin Exp Dermatol 12:444–445

    Article  PubMed  CAS  Google Scholar 

  114. McGovern DP, Jewell DP (2005) Risks and benefits of azathioprine therapy. Gut 54:1055–1059

    Article  PubMed  CAS  Google Scholar 

  115. Connell WR, Kamm MA, Dickson M et al (1994) Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343:1249–1252

    Article  PubMed  CAS  Google Scholar 

  116. Behnam SM, Behnam SE, Koo JY (2005) TNF-alpha inhibitors and congestive heart failure. Skinmed 4:363–368

    PubMed  Google Scholar 

  117. Gupta S, Tripathi CD (2005) Current status of TNF blocking therapy in heart failure. Indian J Med Sci 59:363–366

    Article  PubMed  CAS  Google Scholar 

  118. Levine B, Kalman J, Mayer L et al (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236–241

    Article  PubMed  CAS  Google Scholar 

  119. Rauchhaus M, Doehner W, Francis DP et al (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102:3060–3067

    PubMed  CAS  Google Scholar 

  120. Torre-Amione G, Vooletich MT, Farmer JA (2000) Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs 59:745–751

    Article  PubMed  CAS  Google Scholar 

  121. Torre-Amione G, Kapadia S, Benedict C et al (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201–1206

    Article  PubMed  CAS  Google Scholar 

  122. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003). Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133–140

    Article  PubMed  CAS  Google Scholar 

  123. Khanna D, McMahon M, Furst DE (2004) Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 50:1040–1050

    Article  PubMed  CAS  Google Scholar 

  124. Tanno M, Nakamura I, Kobayashi S et al (2005) New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 23:1–5

    Google Scholar 

  125. Freeman HJ, Flak B (2005) Demyelination-like syndrome in Crohn’s disease after infliximab therapy. Can J Gastroenterol 19:313–316

    PubMed  Google Scholar 

  126. Enayati PJ, Papadakis KA (2005). Association of antitumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 39:303–306

    Article  PubMed  Google Scholar 

  127. Thomas CW Jr, Weinshenker BG, Sandborn WJ (2004) Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 10:28–31

    Article  PubMed  Google Scholar 

  128. Gupta G, Gelfand JM, Lewis JD (2005) Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129:819–826

    Article  PubMed  Google Scholar 

  129. Katz JA (2004) Pregnancy and inflammatory bowel disease. Curr Opin Gastroenterol 20:328–332

    Article  PubMed  Google Scholar 

  130. Froehlich F, Juillerat P, Felley C et al (2005) Treatment of postoperative Crohn’s disease. Digestion 71:49–53

    Article  PubMed  CAS  Google Scholar 

  131. Rutgeerts P (2001) Strategies in the prevention of postoperative recurrence in Crohn’s disease. Best Pract Res Clin Gastroenterol 17:63–73

    Article  CAS  Google Scholar 

  132. Rutgeerts P, Geboes K, Vantrappen G et al (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99:956–963

    PubMed  CAS  Google Scholar 

  133. Rutgeerts P (1994) Recurrence of Crohn’s disease in the neoterminal ileum after ileal resection: is prevention therapy possible? Neth J Med 45:60–64

    PubMed  CAS  Google Scholar 

  134. Olaison G, Smedh K, Sjodahl R (1992) Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 33:331–335

    PubMed  CAS  Google Scholar 

  135. Becker JM (1999) Surgical therapy for ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am 28:371–90, viii-ix

    Article  PubMed  CAS  Google Scholar 

  136. Rutgeerts P, Van Assche G, Vermeire S et al (2005) Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856–861

    Article  PubMed  CAS  Google Scholar 

  137. Rutgeerts P, Hiele M, Geboes K et al (1995) Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 108:1617–1621

    Article  PubMed  CAS  Google Scholar 

  138. Hanauer S, Sandborn W, Rutgeerts P et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSICI trial. Gastroenterology 130:323–333

    Article  PubMed  CAS  Google Scholar 

  139. Papadakis KA, Shaye OA, Vasiliauskas EA et al (2005) Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol 100:75–79

    Article  PubMed  CAS  Google Scholar 

  140. Hanauer SB (2004) Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: overview of randomized clinical studies. Rev Gastroenterol Disord 4(Suppl 3):S18–S24

    PubMed  Google Scholar 

  141. Youdim A, Vasiliauskas EA, Targan SR et al (2004) A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 10:333–338

    Article  PubMed  Google Scholar 

  142. Sandborn WJ, Hanauer S, Loftus EV Jr et al (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 99:1984–1989

    Article  PubMed  CAS  Google Scholar 

  143. Stallmach A, Giese T, Schmidt C (2004) Severe anaphylactic reaction to infliximab: successful treatment with adalimumab — report of a case. Eur J Gastroenterol Hepatol 16:627–630

    Article  PubMed  CAS  Google Scholar 

  144. D’Haens G, Swijsen C, Noman M et al (2001) Etanercept in the treatment of active refractory Crohn’s disease: a single-center pilot trial. Am J Gastroenterol 96:2564–2568

    Article  PubMed  CAS  Google Scholar 

  145. Sandborn WJ, Hanauer SB, Katz S et al (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088–1094

    Article  PubMed  CAS  Google Scholar 

  146. Van den Brande JM, Braat H, van den Brink GR et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124:1774–1785

    Article  PubMed  CAS  Google Scholar 

  147. Rutgeerts P, Lemmens L, Van Assche G et al (2003) Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 17:185–192

    Article  PubMed  CAS  Google Scholar 

  148. Stack WA, Mann SD, Roy AJ et al (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 349:521–524

    Article  PubMed  CAS  Google Scholar 

  149. Sandborn WJ, Feagan BG, Hanauer SB et al (2001) An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120:1330–1338

    Article  PubMed  CAS  Google Scholar 

  150. Feagan BG, Sandborn WJ, Baker JP et al (2005) A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn’s disease. Aliment Pharmacol Ther 21:373–384

    Article  PubMed  CAS  Google Scholar 

  151. Sandborn WJ, Feagan BG, Radford-Smith G et al (2004) CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial. Gut 53:1485–1493

    Article  PubMed  CAS  Google Scholar 

  152. Schreiber S, Rutgeerts P, Fedorak RN et al (2005) A randomized, placebo-controlled trial of Certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 129:807–818

    Article  PubMed  CAS  Google Scholar 

  153. Bauditz J, Wedel S, Lochs H (2002) Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease. Gut 50:196–200

    Article  PubMed  CAS  Google Scholar 

  154. Vasiliauskas EA, Kam LY, Abreu-Martin MT et al (1999) An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology 117:1278–1287

    Article  PubMed  CAS  Google Scholar 

  155. Ehrenpreis ED, Kane SV, Cohen LB et al (1999) Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 117:1271–1277

    Article  PubMed  CAS  Google Scholar 

  156. Bariol C, Meagher AP, Vickers CR et al (2002) Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 17:135–139

    Article  PubMed  CAS  Google Scholar 

  157. Sabate JM, Villarejo J, Lemann M et al (2002) An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn’s disease. Aliment Pharmacol Ther 16:1117–1124

    Article  PubMed  CAS  Google Scholar 

  158. Tilg H, van Montfrans C, van den Ende A et al (2002) Treatment of Crohn’s disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 50:191–195

    Article  PubMed  CAS  Google Scholar 

  159. Fedorak RN, Gangl A, Elson CO et al (2000) Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119:1473–1482

    Article  PubMed  CAS  Google Scholar 

  160. Schreiber S, Fedorak RN, Nielsen OH et al (2000) Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology 119:1461–1472

    Article  PubMed  CAS  Google Scholar 

  161. van Deventer SJ, Elson CO, Fedorak RN (1997) Multiple doses of intravenous interleukin 10 in steroidrefractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 113:383–389

    Article  PubMed  Google Scholar 

  162. Colombel JF, Rutgeerts P, Malchow H et al (2001) Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease. Gut 49:42–46

    Article  PubMed  CAS  Google Scholar 

  163. Lindsay JO, Ciesielski CJ, Scheinin T et al (2003) Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 52:363–369

    Article  PubMed  CAS  Google Scholar 

  164. Sands BE, Bank S, Sninsky CA et al (1999) Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn’s disease. Gastroenterology 117:58–64

    Article  PubMed  CAS  Google Scholar 

  165. Sands BE, Winston BD, Salzberg B et al (2002) Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease. Aliment Pharmacol Ther 16:399–406

    Article  PubMed  CAS  Google Scholar 

  166. Sandborn WJ, Yednock TA (2003) Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 98:2372–2382

    Article  PubMed  CAS  Google Scholar 

  167. Ghosh S, Goldin E, Gordon FH et al (2003) Natalizumab for active Crohn’s disease. N Engl J Med 348:24–32

    Article  PubMed  CAS  Google Scholar 

  168. Sandborn WJ, Colombel JF, Enns R et al (2005) Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 353:1912–1925

    Article  PubMed  CAS  Google Scholar 

  169. Gordon FH, Lai CW, Hamilton MI et al (2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology 121:268–274

    Article  PubMed  CAS  Google Scholar 

  170. Berger T, Deisenhammer F (2005) Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis. N Engl J Med 353:1744–1746; author reply 1744–1746

    Article  PubMed  CAS  Google Scholar 

  171. Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375–381

    Article  PubMed  CAS  Google Scholar 

  172. Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353:362–368

    Article  PubMed  Google Scholar 

  173. Berger JR, Koralnik IJ (2005) Progressive multifocal leukoencephalopathy and natalizumab—unforeseen consequences. N Engl J Med 353:414–416

    Article  PubMed  CAS  Google Scholar 

  174. Sandborn WJ (1997) Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol 92:876–879

    PubMed  CAS  Google Scholar 

  175. Ierardi E, Principi M, Francavilla R et al (2001) Oral tacrolimus long-term therapy in patients with Crohn’s disease and steroid resistance. Aliment Pharmacol Ther 15:371–377

    Article  PubMed  CAS  Google Scholar 

  176. Sandborn WJ, Present DH, Isaacs KL et al (2003) Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 125:380–388

    Article  PubMed  CAS  Google Scholar 

  177. Gonzalez-Lama Y, Abreu L, Vera MI et al (2005) Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn’s disease: a pilot study. Inflamm Bowel Dis 11:8–15

    Article  PubMed  Google Scholar 

  178. Fukuda A, Nakase H, Seno H et al (2005) Refractory enterovesical and duodenocolic fistulas in Crohn’s disease successfully managed with tacrolimus. J Gastroenterol 40:433–435

    Article  PubMed  Google Scholar 

  179. Miehsler W, Reinisch W, Moser G et al (2001) Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn’s disease? Am J Gastroenterol 96:782–787

    Article  PubMed  CAS  Google Scholar 

  180. Neurath MF, Wanitschke R, Peters M et al (1999) Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 44:625–628

    Article  PubMed  CAS  Google Scholar 

  181. Ford AC, Towler RJ, Moayyedi P et al (2003) Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 17:1365–1369

    Article  PubMed  CAS  Google Scholar 

  182. Fickert P, Hinterleitner TA, Wenzl HH et al (1998) Mycophenolate mofetil in patients with Crohn’s disease. Am J Gastroenterol; 93:2529–2532

    Article  PubMed  CAS  Google Scholar 

  183. Fellermann K, Steffen M, Stein J et al (2000) Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14:171–176

    Article  PubMed  CAS  Google Scholar 

  184. Wenzl HH, Hinterleitner TA, Aichbichler BW et al (2004) Mycophenolate mofetil for Crohn’s disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 19:427–434

    Article  PubMed  CAS  Google Scholar 

  185. Moreels TG, Pelckmans PA (2005) Gastrointestinal parasites: potential therapy for refractory inflammatory bowel diseases. Inflamm Bowel Dis 11:178–184

    Article  PubMed  Google Scholar 

  186. Elliott DE, Li J, Blum A et al (2003) Exposure to schistosome eggs protects mice from TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 284:G385–391

    PubMed  CAS  Google Scholar 

  187. Moreels TG, Nieuwendijk RJ, De Man JG et al (2004) Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. Gut 53:99–107

    Article  PubMed  CAS  Google Scholar 

  188. Khan WI, Blennerhasset PA, Varghese AK et al (2002) Intestinal nematode infection ameliorates experimental colitis in mice. Infect Immun 70:5931–5937

    Article  PubMed  CAS  Google Scholar 

  189. Summers RW, Elliott DE, Qadir K et al (2003) Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 98:2034–2041

    Article  PubMed  Google Scholar 

  190. Summers RW, Elliott DE, Urban JF Jr et al (2005) Trichuris suis therapy in Crohn’s disease. Gut 54:87–90

    Article  PubMed  CAS  Google Scholar 

  191. Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620–1633

    Article  PubMed  Google Scholar 

  192. Fedorak RN, Madsen KL (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286–299

    Article  PubMed  Google Scholar 

  193. Egan LJ, Sandborn WJ (2005) Positioning novel biologic, probiotic, and apheresis therapies for Crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep 7:485–491

    PubMed  Google Scholar 

  194. Schultz M, Timmer A, Herfarth HH et al (2004) Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol 4:5

    Article  PubMed  Google Scholar 

  195. Bousvaros A, Guandalini S, Baldassano RN et al (2005) A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 11:833–839

    Article  PubMed  Google Scholar 

  196. Prantera C, Scribano ML, Falasco G et al (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomized controlled trial with Lactobacillus GG. Gut 51:405–409

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology Policlinico “G.B. Rossi”, University of Verona, Verona, Italy

    Luca Frulloni & Chiara Scattolini

  2. Unit of Digestive Endoscopy Policlinico “G.B. Rossi”, University of Verona, Verona, Italy

    Laura Bernardoni

  3. Department of Biomedical and Surgical Sciences Division of Gastroenterology, Policlinico “G.B. Rossi”, Verona, Italy

    Italo Vantini

Authors
  1. Luca Frulloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Bernardoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiara Scattolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Italo Vantini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery and Gastroenterology, University of Verona, Verona, Italy

    Gian Gaetano Delaini

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Italia

About this chapter

Cite this chapter

Frulloni, L., Bernardoni, L., Scattolini, C., Vantini, I. (2006). Biological Approach in the Treatment of Crohn’s Disease. In: Delaini, G.G. (eds) Inflammatory Bowel Disease and Familial Adenomatous Polyposis. Springer, Milano. https://doi.org/10.1007/88-470-0434-9_16

Download citation

  • DOI: https://doi.org/10.1007/88-470-0434-9_16

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0433-7

  • Online ISBN: 978-88-470-0434-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation